ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0800

CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis

Shozo Ohtsuki1, Jose Morales2, Yuki Sato2, Chenyao Wang2, Matthew Koster3, Kenneth Warrington3, Gerald J. Berry4, Jorg Goronzy3 and Cornelia M. Weyand5, 1Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Stanford University School of Medicine, Stanford, CA, 5Mayo Clinic School of Medicine and Stanford University, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, cytokines, giant cell arteritis, T Cell, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of the granulomatous lesions are CD4+ T cells and macrophages, some of which differentiate into multinucleated giant cells. Lesional CD4+ T cells undergo clonal expansion and vasculitic arteries contain mRNA and protein of multiple T cell effector cytokines, but it is unclear whether GCA patients possess specialized T cell subsets that promote macrophage multinucleation and granuloma formation in the vessel wall.

Methods: Patients with a positive temporal artery biopsy or unequivocal evidence for GCA aortitis were enrolled into the study. Patients with granulomatosis with polyangiitis served as disease controls and age-matched healthy controls were recruited through the Biobank. Tissue lesions were analyzed by immunofluorescence staining of temporal artery sections. T cell phenotyping relied on multiparametric flow cytometry and T cell reactivity was tested against anti-CD3-loaded antigen-presenting cells. The functional relevance of CD4+ T cell subsets was examined in immunodeficient mice engrafted with human arteries and immuno-reconstituted with immune cell populations from GCA patients (human artery-SCID chimeric mice).

Results: Memory CD4+ T cells isolated from GCA patients and age-matched controls fell into 10 clusters based on the combinatorial expression of 8 immunoreceptors (CD45RA, CCR7, PD1, LAG3, CD226, CD96, TIGIT, TIM3). GCA patients selectively expanded CD4+CD96+ memory T cells (10.9% control, 16.9% GCA), while CD4+TIGIThigh populations were reduced (24.5% control, 17.4% GCA). CD4+CD96low T cells, generated by siRNA transfection, induced vascular inflammation in artery-SCID chimeric mice (p=0.0044), indicating that CD96 delivers a negative signal and opposes T cell activation. The expansion of CD4+CD96+ T cells was dependent on interaction of CD96 with its ligand CD155 on the surface of antigen-presenting cells. Maldifferentiation of CD4+ T cells in GCA patients was associated with the excessive production of three effector cytokines: IL-9 (p=0.02), IL-21 (p=0.028), and IFN-γ (p=0.03). In vivo testing identified IL-9 as a strong driver of vascular inflammation, associated with marked damage of the vessel wall smooth muscle cell layer. Anti-IL-9 treatment efficiently suppressed vascular inflammation (p=0.0025). In single cell RNA sequencing from tissue derived T cells, CD96 expression mapped to the T follicular helper cell population.

Conclusion: In GCA patients, the differentiation of CD4+ memory T cells is abnormal, leading to the selective expansion of immature and multifunctional T cells, while the transition into effector T cells is decelerated. The underlying defect lies in antigen-presenting cells that withdraw opposing signals as T cells progress through their differentiation cycle. Resulting CD4+ memory T cells hyperproduce IL-9, IL-21, and IFN-γ. Blocking T cell effector functions in GCA will therefore require targeting an array of cytokines.


Disclosures: S. Ohtsuki: None; J. Morales: None; Y. Sato: None; C. Wang: None; M. Koster: None; K. Warrington: Bristol-Myers Squibb(BMS), 5, Chemocentryx, 1, 6, Eli Lilly, 5, kiniksa, 5; G. Berry: None; J. Goronzy: AbbVie/Abbott, 1, Bristol-Myers Squibb(BMS), 1, Gilead, 1; C. Weyand: AbbVie/Abbott, 1, Bristol-Myers Squibb(BMS), 1, Gilead, 1.

To cite this abstract in AMA style:

Ohtsuki S, Morales J, Sato Y, Wang C, Koster M, Warrington K, Berry G, Goronzy J, Weyand C. CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cd4-cd96-t-cells-are-pathogenic-effector-cells-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd4-cd96-t-cells-are-pathogenic-effector-cells-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology